Successful development and application of precision oncology approaches require robust elucidation of the genomic landscape of a patient\u27s cancer and the ability to monitor therapy-induced genomic changes in the tumour in an inexpensive and minimally invasive manner. Thanks to recent advances in sequencing technologies, "liquid biopsy", the sampling of patient\u27s bodily fluids such as blood, is considered as one of the most promising approaches to achieve this goal. In many cancer patients, especially those with advanced metastatic disease, deep sequencing of cell-free DNA (cfDNA) obtained from patient\u27s blood yields a mixture of reads originating from the normal DNA and from multiple tumour subclones - called circulating tumour DNA...
Pre-symptomatic screening of genetic alterations might help identify subpopulations of individuals t...
Pre-symptomatic screening of genetic alterations might help identify subpopulations of individuals t...
Accurate estimation of systemic tumor load from the blood of cancer patients has enormous potential....
textabstractThe use of blood-circulating cell-free DNA (cfDNA) as 'liquid-biopsy' is explored worldw...
Analyzing cell-free DNA (cfDNA) as a source of circulating tumor DNA is useful for diagnosing or mon...
Recently, many genome-wide profiling studies provided insights into the molecular make-up of major c...
Early detection of cancer saves lives, but an effective detection strategy in public health settings...
Liquid biopsies, using analytes such as circulating tumour DNA (ctDNA), can detect and quantify canc...
The increased importance of cancer genotyping in guiding cancer treatment has created a need for eff...
Cell-free DNA (cfDNA), acquired through non-invasive liquid biopsies, provides a new opportunity for...
Cell-free plasma DNA (cfDNA) is defined as fragments of DNA present in the extracellular fluid. Thes...
Accurate estimation of systemic tumor load from the blood of cancer patients has enormous potential....
Collection of tumor samples is not always feasible in non-small cell lung cancer (NSCLC) patients, a...
It is possible to call single-nucleotide variant (SNV) in cell-free DNA (cfDNA), but the accuracy of...
Collection of tumor samples is not always feasible in non-small cell lung cancer (NSCLC) patients, a...
Pre-symptomatic screening of genetic alterations might help identify subpopulations of individuals t...
Pre-symptomatic screening of genetic alterations might help identify subpopulations of individuals t...
Accurate estimation of systemic tumor load from the blood of cancer patients has enormous potential....
textabstractThe use of blood-circulating cell-free DNA (cfDNA) as 'liquid-biopsy' is explored worldw...
Analyzing cell-free DNA (cfDNA) as a source of circulating tumor DNA is useful for diagnosing or mon...
Recently, many genome-wide profiling studies provided insights into the molecular make-up of major c...
Early detection of cancer saves lives, but an effective detection strategy in public health settings...
Liquid biopsies, using analytes such as circulating tumour DNA (ctDNA), can detect and quantify canc...
The increased importance of cancer genotyping in guiding cancer treatment has created a need for eff...
Cell-free DNA (cfDNA), acquired through non-invasive liquid biopsies, provides a new opportunity for...
Cell-free plasma DNA (cfDNA) is defined as fragments of DNA present in the extracellular fluid. Thes...
Accurate estimation of systemic tumor load from the blood of cancer patients has enormous potential....
Collection of tumor samples is not always feasible in non-small cell lung cancer (NSCLC) patients, a...
It is possible to call single-nucleotide variant (SNV) in cell-free DNA (cfDNA), but the accuracy of...
Collection of tumor samples is not always feasible in non-small cell lung cancer (NSCLC) patients, a...
Pre-symptomatic screening of genetic alterations might help identify subpopulations of individuals t...
Pre-symptomatic screening of genetic alterations might help identify subpopulations of individuals t...
Accurate estimation of systemic tumor load from the blood of cancer patients has enormous potential....